{"title": "Immune response and outcome of high-risk neuroblastoma patients immunized with anti-idiotypic antibody ganglidiomab: a compassionate use program", "author": "Klingel; Leah Bernadette", "url": null, "hostname": null, "description": "Background and Aim: High-risk neuroblastoma (HR-NB) is associated with a dismal prognosis despite the utilization of multimodal treatment, including therapy with an anti-GD2 monoclonal antibody (mAb). Here we investigated the use of an anti-idiotypic vaccine (ganglidiomab) in patients with HR-NB with or without relapse. Ganglidiomab is a murine monoclonal anti-idiotypic antibody and a structural mimic of GD2. Patients and Methods: In this compassionate use program, seven HR-NB patients (two with relapsed disease) who achieved complete remission after salvage therapy were enrolled. They received 6-22 subcutaneous vaccine injections every two weeks. Each subcutaneous vaccine injection consisted of 0.5mg of ganglidiomab with 1.67mg aluminum as adjuvant. The immune response was quantified by ELISA methods. We investigated the vaccine-induced antibody response against ganglidiomab (vaccine), against ganglidiximab (a human-mouse chimeric variant of ganglidiomab), as well as against GD2, in immunized patients and determined the time to relapse or progression to last follow-up. Results: Among the patients enrolled, 6/7 showed an immune response against ganglidiomab as well as an anti-ganglidiximab seroconversion. The non-responding patient had a haploidentical stem cell transplantation as part of the previous treatment, which is associated with B-cell immunodeficiency. However, an anti-GD2 seroconversion was only seen in 2/7 patients. Common toxicities were self-limited, including injection-related local reactions. No fever, pain, neuropathy, or grade 3/4 toxicities occurred during or post-treatment. All immunized patients did not experience a relapse or progression of their neuroblastoma with a median range of 56 months and 16 days from the first vaccine dose to the last follow-up, which contrasts with what is expected from historical control cohorts. Conclusions: This is the first in man use of the anti-idiotype vaccine ganglidiomab in HR-NB patients. The vaccine was well-tolerated, and none of the vaccinated patients experienced a relapse or progression. These findings provide an important basis for the design of prospective clinical trials.", "sitename": null, "date": "2022-03-04", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Bitte verwenden Sie diesen Link, wenn Sie dieses Dokument zitieren oder verlinken wollen:\n[https://nbn-resolving.org/urn:nbn:de:gbv:9-opus-59793](https://nbn-resolving.org/urn:nbn:de:gbv:9-opus-59793)\nImmune response and outcome of high-risk neuroblastoma patients immunized with anti-idiotypic antibody ganglidiomab: a compassionate use program\n- Background and Aim: High-risk neuroblastoma (HR-NB) is associated with a dismal prognosis despite the utilization of multimodal treatment, including therapy with an anti-GD2 monoclonal antibody (mAb). Here we investigated the use of an anti-idiotypic vaccine (ganglidiomab) in patients with HR-NB with or without relapse. Ganglidiomab is a murine monoclonal anti-idiotypic antibody and a structural mimic of GD2. Patients and Methods: In this compassionate use program, seven HR-NB patients (two with relapsed disease) who achieved complete remission after salvage therapy were enrolled. They received 6-22 subcutaneous vaccine injections every two weeks. Each subcutaneous vaccine injection consisted of 0.5mg of ganglidiomab with 1.67mg aluminum as adjuvant. The immune response was quantified by ELISA methods. We investigated the vaccine-induced antibody response against ganglidiomab (vaccine), against ganglidiximab (a human-mouse chimeric variant of ganglidiomab), as well as against GD2, in immunized patients and determined the time to relapse or progression to last follow-up. Results: Among the patients enrolled, 6/7 showed an immune response against ganglidiomab as well as an anti-ganglidiximab seroconversion. The non-responding patient had a haploidentical stem cell transplantation as part of the previous treatment, which is associated with B-cell immunodeficiency. However, an anti-GD2 seroconversion was only seen in 2/7 patients. Common toxicities were self-limited, including injection-related local reactions. No fever, pain, neuropathy, or grade 3/4 toxicities occurred during or post-treatment. All immunized patients did not experience a relapse or progression of their neuroblastoma with a median range of 56 months and 16 days from the first vaccine dose to the last follow-up, which contrasts with what is expected from historical control cohorts. Conclusions: This is the first in man use of the anti-idiotype vaccine ganglidiomab in HR-NB patients. The vaccine was well-tolerated, and none of the vaccinated patients experienced a relapse or progression. These findings provide an important basis for the design of prospective clinical trials.\n- Hintergrund: Das Hochrisiko-Neuroblastom (HR-NB) ist trotz multimodaler Behandlung, einschlie\u00dflich einer Therapie mit einem monoklonalen Anti-GD2-Antik\u00f6rper (mAb), mit einer schlechten Prognose assoziiert. Hier untersuchten wir die Verwendung eines antiidiotypischen Impfstoffs (Ganglidiomab) bei Patienten mit HR-NB mit oder ohne Rezidiv. Ganglidiomab ist ein muriner monoklonaler antiidiotypischer Antik\u00f6rper und imitiert strukturell und funktionell das Disialogangliosid GD2. Patienten und Methoden: In dieses Heilversuchsprogramm wurden sieben HR-NB-Patienten (zwei mit rezidivierter Erkrankung) aufgenommen, die nach einer Salvage-Therapie eine vollst\u00e4ndige Remission erreichten. Sie erhielten alle zwei Wochen 6-22 subkutane Impfstoffinjektionen. Jede subkutane Impfstoffinjektion bestand aus 0,5 mg Ganglidiomab mit 1,67 mg Aluminiumhydroxid als Adjuvant. Die Immunantwort wurde durch ELISA quantifiziert. Wir untersuchten die impfstoffinduzierte Antik\u00f6rperantwort gegen Ganglidiomab (Impfstoff), gegen Ganglidiximab (eine human-murin chim\u00e4re Variante von Ganglidiomab) sowie gegen GD2 bei immunisierten Patienten und bestimmten die Zeit bis zum Rezidiv oder der Progression. Ergebnisse: Unter den eingeschlossenen Patienten zeigten 6/7 eine Immunantwort gegen Ganglidiomab sowie eine Anti-Ganglidiximab-Serokonversion. Der nicht ansprechende Patient hatte im Rahmen der vorherigen Behandlung eine haploidentische Stammzelltransplantation, die mit einer B-Zell-Immunschw\u00e4che einhergeht. Eine Anti-GD2-Serokonversion wurde bei 2/7 Patienten beobachtet. Nebenwirkungen waren selbstlimitierend, einschlie\u00dflich injektionsbedingter lokaler Reaktionen. W\u00e4hrend oder nach der Behandlung traten weder Fieber, Schmerzen, Neuropathie noch Grad-3/4-Toxizit\u00e4ten auf. Bei allen immunisierten Patienten trat kein Rezidiv und kein Fortschreiten ihres Neuroblastoms im Beobachtungszeitraum auf, mit einer mittleren Zeitspanne von 56 Monaten und 16 Tagen von der ersten Impfdosis bis zur letzten Nachuntersuchung, was im Gegensatz zu dem steht, was von historischen Kontrollkohorten erwartet wird. Schlussfolgerungen: Dies ist die erste Anwendung des Anti-Idiotyp-Impfstoffs Ganglidiomab bei Patienten mit einem HR-NB. Der Impfstoff wurde gut vertragen, und keiner der geimpften Patienten erlitt ein Rezidiv oder eine Progression. Diese Erkenntnisse bilden eine wichtige Grundlage f\u00fcr das Design prospektiver klinischer Studien.\n|Author:|", "language": null, "image": null, "pagetype": null, "links": ["/home/index/language/language/de/rmodule/frontdoor/rcontroller/index/raction/index/docId/5979", "/auth/login/docId/5979/rmodule/frontdoor/rcontroller/index/raction/index", "/home", "/home", "/solrsearch", "/solrsearch/browse", "/publish", "https://ub.uni-greifswald.de/serviceangebote/fuer-wissenschaftlerinnen/publizieren", "javascript:void(0)", "https://nbn-resolving.org/urn:nbn:de:gbv:9-opus-59793", "/solrsearch/index/search/searchtype/authorsearch/author/Leah+Bernadette+Klingel", "/files/5979/Dissertation_Klingel_2021.pdf", "/citationExport/index/download/docId/5979/output/bibtex", "/citationExport/index/download/docId/5979/output/ris", "http://twitter.com/share?url=https://epub.ub.uni-greifswald.de/frontdoor/index/index/docId/5979", "https://scholar.google.de/scholar?hl=en&q=\"Immune response and outcome of high-risk neuroblastoma patients immunized with anti-idiotypic antibody ganglidiomab: a compassionate use program\"&as_sauthors=Leah Bernadette+Klingel&as_ylo=2022&as_yhi=2022", "javascript:void(0)", "/solrsearch/index/search/searchtype/authorsearch/author/Leah+Bernadette+Klingel", "https://nbn-resolving.org/urn:nbn:de:gbv:9-opus-59793", "/solrsearch/index/search/searchtype/authorsearch/referee/Holger+Lode", "/solrsearch/index/search/searchtype/authorsearch/referee/Patrick+Hundsd%C3%B6rfer", "/solrsearch/index/search/searchtype/collection/id/16291", "/solrsearch/index/search/searchtype/collection/id/73", "/home/index/contact", "/home/index/imprint", "/home/index/datenschutz", "/crawlers/sitelinks"]}